Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins.
Junkai WangAlexander B SaltzmanEric J JaehnigJonathan T LeiAnna MalovannayaMatthew V HoltMeggie N YoungMothaffar F RimawiFoluso O AdemuyiwaMeenakshi AnuragBeom-Jun KimMatthew J EllisPublished in: Cancer research communications (2023)
The identification of pretreatment predictive biomarkers for pCR in response to neoadjuvant chemotherapy would advance precision treatment for TNBC. To complement standard proteogenomic discovery profiling, a KIPA was deployed and unexpectedly identified a seven-member non-kinase PBP pCR-associated signature. Individual members served diverse pathways including IFN gamma response, nuclear import of DNA repair proteins, and cell death.
Keyphrases